As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17. Further, the revenues are estimated to increase by 5% to $12.1 billion during 1Q18 as compared to revenues of $11.5 billion in 1Q17. Also, Novartis is expected to report earnings per share of $1.26 during 1Q18 as compared to EPS of $1.13 during 1Q17.
The above chart shows analysts’ recommendations for Novartis over the last 12 months.
Novartis’s stock price has increased by nearly 9.5% during the last 12 months but decreased by ~1.4% in 2018 year-to-date. Further, analysts estimate the stock has a potential to return ~18.5% over the next 12 months. Wall Street analysts have a 12-month target price of $98.06 per share as compared to the last price of $82.76 per share as of March 8, 2018.
There are four analysts tracking Novartis ADR. From these, two analysts recommend a “buy,” while one analyst recommends a “hold,” and one analyst recommends a “sell.” The consensus rating for Novartis ADR is 2.5, representing a moderate buy for long-term growth investors as well as value investors.
Also, there are 30 analysts covering Novartis’s stock listed on Six Swiss Exchange. Of these, 15 analysts recommend a “buy,” 12 analysts recommend a “hold,” and three analysts recommend a “sell.” The consensus rating for Novartis stands at 2.4, which represents a moderate buy for value investors.
Notably, the Vanguard Total World Stock ETF (VT) holds 10.2% of its total investments in healthcare companies. VT holds 0.4% in Novartis (NVS), 0.7% in Johnson & Johnson (JNJ), 0.4% in Pfizer (PFE), and 0.3% in AbbVie (ABBV).